Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic laxative. Polyethylene glycol (PEG) 3350 and sodium sulfate act as osmotic agents that retain water in the colon, increasing stool water content and inducing diarrhea. Ascorbic acid and sodium ascorbate enhance colonic fluid retention and secretion through organic anion transporters.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Bowel preparation before colonoscopy in adults (FDA approved),Bowel preparation for colorectal surgery (off-label),Management of severe constipation (off-label)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Adults: 240 m L (or 2 sachets) reconstituted to 1 L water, administered orally or via nasogastric tube, in divided doses (e.g., 240 m L every 10-15 minutes) to a total volume of 1 L, followed by additional clear liquids as needed. For colonoscopy preparation, the typical regimen is a split-dose: first half (500 m L) in the evening before procedure, second half (500 m L) at least 3-5 hours before procedure.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
PEG 3350: Not applicable (minimal systemic absorption). Ascorbic acid: ~10-20 hours (dose-dependent, renal saturable reabsorption).
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Not metabolized; excreted unchanged in feces.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily fecal (≥96%) as intact PEG 3350; absorbed fraction of electrolytes and ascorbate renally eliminated. Renal excretion of PEG <0.2%.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
PEG 3350: Negligible; Ascorbic acid: ~25% bound to albumin.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
PEG 3350: ~0 L/kg (confined to GI tract); Ascorbic acid: ~0.4-0.6 L/kg (distributes into total body water).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral: PEG 3350 <0.06% (systemic); Ascorbic acid: 80-90% at low doses, decreases with high doses (saturable absorption).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Contraindicated in patients with creatinine clearance < 30 m L/min due to risk of fluid and electrolyte disturbances. For GFR 30-60 m L/min: no dose adjustment required but monitor electrolytes and fluid status closely. For GFR > 60 m L/min: no adjustment needed.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustment recommended for hepatic impairment. Use with caution in patients with severe hepatic impairment (Child-Pugh class C) due to potential fluid overload and electrolyte imbalances; consider alternative bowel preparation.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Children (≥6 months to 18 years): For colonoscopy, dose based on age and weight: 6 months to 1 year (7-10 kg): 125 m L (1/4 sachet) in 250 m L water; 1-2 years (10-13 kg): 250 m L (1/2 sachet) in 500 m L water; 2-4 years (13-17 kg): 375 m L (3/4 sachet) in 750 m L water; 4-12 years (17-33 kg): 500 m L (1 sachet) in 1 L water; >12 years: 1 L (2 sachets) in 2 L water. Administer orally in divided doses (e.g., 25-50 m L/kg/h) until clear rectal effluent. Not recommended in infants <6 months.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Elderly patients (≥65 years): No dose adjustment required but use with caution due to increased risk of fluid and electrolyte disturbances, dehydration, and renal impairment. Monitor hydration status, electrolytes, and renal function (creatinine and BUN) before and after administration. Consider split-dose regimen to minimize volume load and ensure adequate hydration.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of electrolyte abnormalities (especially hypernatremia, hypokalemia) and fluid imbalance,Risk of cardiac arrhythmias, including QT prolongation, in patients with electrolyte disorders or taking QT-prolonging drugs,Risk of renal impairment, especially in patients with pre-existing kidney disease or taking nephrotoxic drugs,Seizures secondary to electrolyte abnormalities,Serious adverse reactions including ulcerative colitis, ischemic colitis, and aspiration
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Gastrointestinal obstruction or ileus,Gastric retention,Bowel perforation,Toxic colitis or toxic megacolon,Hypersensitivity to any component,Severe renal impairment (Cr Cl < 30 m L/min),Severe electrolyte abnormalities (e.g., hypernatremia, hypokalemia)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid solid food and dairy products during bowel preparation. Only clear liquids (e.g., water, clear broth, apple juice, black coffee/tea) are permitted. Do not consume alcohol.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid combination is used for bowel cleansing prior to colonoscopy. There are no adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Based on the mechanism of action and lack of systemic absorption of the polyethylene glycol and sulfate components, the risk of teratogenicity is considered low. However, dehydration and electrolyte imbalances secondary to the purgative effect could theoretically pose risks, particularly in the first trimester. The FDA pregnancy category is not assigned; however, most sources consider it low risk with cautious use if clearly needed.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Excretion into human milk is unknown for the components. Polyethylene glycol (PEG-3350) is not absorbed systemically after oral administration, so it is unlikely to enter breast milk in significant amounts. Sodium sulfate, sodium chloride, potassium chloride, and ascorbic acid/sodium ascorbate are normal dietary constituents and are present in breast milk at baseline. The M/P ratio has not been established. Use during breastfeeding is generally considered compatible, but the manufacturer recommends caution due to possible gastrointestinal effects in the infant. Ideally, avoid use in nursing mothers unless the benefit outweighs the risk.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No pharmacokinetic studies have been performed in pregnant women to determine if dose adjustments are necessary. The components are minimally absorbed or are endogenous substances; therefore, pregnancy-induced changes in gastrointestinal motility or volume of distribution are unlikely to require dose adjustment. However, due to increased risk of dehydration and electrolyte imbalance in pregnancy, some clinicians recommend using a lower dose or a split-dose regimen. The standard adult dose (e.g., 1 liter of solution) may be used if the benefit outweighs the risk, but close monitoring is advised.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Requires adequate hydration to prevent renal injury; rare cases of osmotic demyelination syndrome reported with rapid correction of hyponatremia; contra indicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Do not take within 1 hour of other oral medications as absorption may be reduced.,Complete the entire course: split-dose regimen or single dose per prescribing information.,Expect watery stools; stay near a restroom after starting the dose.,Consume only clear liquids during preparation – no red or purple dyes.,Seek medical attention for severe abdominal pain, vomiting, or inability to tolerate the solution.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Ascorbic acid (vitamin C) can chelate bortezomib, a boronic acid-based proteasome inhibitor, forming a complex that reduces the free concentration of bortezomib in plasma. This chemical interaction primarily occurs in vitro and may also occur in vivo, potentially leading to decreased proteasome inhibition and reduced anticancer efficacy of bortezomib. Clinically, concurrent use of ascorbic acid may compromise bortezomib's therapeutic effect in multiple myeloma or mantle cell lymphoma treatment."
"Ascorbic acid (vitamin C) may reduce the bioavailability of cyclosporine, a calcineurin inhibitor immunosuppressant, potentially leading to decreased serum cyclosporine concentrations and increased risk of transplant rejection. The interaction is thought to occur via alteration of gastrointestinal pH or chelation affecting cyclosporine absorption. Clinical outcomes could include subtherapeutic immunosuppression requiring dosage adjustments."
"Ascorbic acid (vitamin C) can reduce the serum concentration of amphetamine by acidifying the urine, which increases the renal clearance of amphetamine. This occurs because amphetamine is a weak base, and in acidic urine, it is more ionized and less likely to be reabsorbed in the renal tubules, leading to enhanced elimination. Clinically, this may result in decreased amphetamine efficacy, potentially worsening symptoms in patients being treated for attention deficit hyperactivity disorder or narcolepsy."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID is a Electrolyte that works by Osmotic laxative. Polyethylene glycol (PEG) 3350 and sodium sulfate act as osmotic agents that retain water in the colon, increasing stool water content and inducing diarrhea. Ascorbic acid and sodium ascorbate enhance colonic fluid retention and secretion through organic anion transporters.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID is: Adults: 240 m L (or 2 sachets) reconstituted to 1 L water, administered orally or via nasogastric tube, in divided doses (e.g., 240 m L every 10-15 minutes) to a total volume of 1 L, followed by additional clear liquids as needed. For colonoscopy preparation, the typical regimen is a split-dose: first half (500 m L) in the evening before procedure, second half (500 m L) at least 3-5 hours before procedure.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID is classified as Category A/B. PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid combination is used for bowel cleansing prior to colonoscopy. There are no adequat. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.